Dunhill Financial’s Procept Biorobotics PRCT Stock Holding History

Dunhill Financial’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$28	–	1819
2026 Q1	$28	Hold	1	–	–	﹤0.01%	1720
2025 Q4	$35	Buy	+1	New	+$33	﹤0.01%	1777

Other funds holding PRCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dunhill Financial's PRCT Position: Q2 2026 in Review

Dunhill Financial sold out of Procept Biorobotics (PRCT) in Q2 2026, closing a stake of 1 share — an estimated $28 sold.

Dunhill Financial first reported a position in PRCT in Q4 2025 and held it in 2 quarters. The position peaked at $35 in Q4 2025. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

Dunhill Financial reported no remaining Procept Biorobotics position as of Q2 2026 after selling out during the quarter.
Dunhill Financial sold 1 Procept Biorobotics share in Q2 2026, an estimated $28.
Dunhill Financial first reported a position in Procept Biorobotics in Q4 2025 and held it in 2 quarters.
Dunhill Financial's Procept Biorobotics position peaked at $35 in Q4 2025.
254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.